The study will evaluate the effect of oral contraceptive (birth control pill) on the blood level of lanabecestat when both are given together. Side effects will be monitored and documented. This study will last up to 27 days for each participant, not including screening. Screening is required within 42 days prior to first dose.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Administered orally
Administered orally
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Singapore, Singapore
Pharmacokinetics (PK): Area Under The Concentration Curve (AUC) of Ethinyl Estradiol
PK: AUC of Ethinyl Estradiol
Time frame: Baseline though 120 hours after administration of the study drug (lanabecestat)
PK: AUC of Levonorgestrel
PK: AUC of Levonorgestrel
Time frame: Baseline though 120 hours after administration of the study drug (lanabecestat)
PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol
PK: Cmax of Ethinyl Estradiol
Time frame: Baseline though 120 hours after administration of the study drug (lanabecestat)
PK: Cmax of Levonorgestrel
PK: Cmax of Levonorgestrel
Time frame: Baseline though 120 hours after administration of the study drug (lanabecestat)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.